Terumo Corporation, a leading global medical technology company headquartered in Japan, has been at the forefront of healthcare innovation since its founding in 1921. With a strong presence in regions such as Europe, Asia, and the Americas, Terumo operates primarily within the medical devices industry, focusing on areas like vascular intervention, blood management, and surgical products. Renowned for its commitment to quality and safety, Terumo offers a diverse range of core products, including advanced catheter systems, blood collection devices, and infusion systems. These products are distinguished by their cutting-edge technology and user-centric design, ensuring optimal performance in clinical settings. As a trusted partner in healthcare, Terumo has achieved significant milestones, including numerous certifications and recognitions for excellence in medical technology, solidifying its position as a key player in the global market.
How does Terumo's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Terumo's score of 60 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Terumo Corporation reported total carbon emissions of approximately 2,562,700 kg CO2e, with Scope 1 emissions at about 1,015,800 kg CO2e and Scope 2 emissions (location-based) at approximately 1,191,800 kg CO2e. The company also disclosed significant Scope 3 emissions, including 853,900 kg CO2e from business travel and 636,000 kg CO2e from employee commuting. For the year 2023, Terumo's emissions in Japan were approximately 92,643,000 kg CO2e, with Scope 1 at about 42,313,000 kg CO2e and Scope 2 at approximately 50,329,000 kg CO2e. Globally, the total emissions were reported at about 206,031,000 kg CO2e, with Scope 1 and 2 emissions combined at the same figure. Terumo has set ambitious reduction targets, aiming to reduce absolute Scope 1 and 2 GHG emissions by 30% by 2030 and 80% by 2050, both from a 2018 baseline. Additionally, the company commits to reducing Scope 3 emissions by 60% per unit of revenue over the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect a commitment to maintaining global temperature rise within 1.5°C. Furthermore, Terumo aims to achieve carbon neutrality by FY2040, encompassing all scopes of emissions. This commitment underscores the company's proactive approach to addressing climate change and reducing its carbon footprint in the healthcare sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2005 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | 0,000,000,000 | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Terumo is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
